Candel Change To Liabilities vs Begin Period Cash Flow Analysis

CADL Stock

USD 4.71 0.00 0.00%

Candel Therapeutics financial indicator trend analysis is way more than just evaluating Candel Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Candel Therapeutics is a good investment. Please check the relationship between Candel Therapeutics Change To Liabilities and its Begin Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.

Change To Liabilities vs Begin Period Cash Flow

Change To Liabilities vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Candel Therapeutics Change To Liabilities account and Begin Period Cash Flow. At this time, the significance of the direction appears to have pay attention.

The correlation between Candel Therapeutics' Change To Liabilities and Begin Period Cash Flow is -0.72. Overlapping area represents the amount of variation of Change To Liabilities that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Candel Therapeutics, assuming nothing else is changed. The correlation between historical values of Candel Therapeutics' Change To Liabilities and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change To Liabilities of Candel Therapeutics are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Change To Liabilities i.e., Candel Therapeutics' Change To Liabilities and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.72

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Change To Liabilities

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Candel Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Candel Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.The value of Selling General Administrative is expected to slide to about 10.2 M. Issuance Of Capital Stock is expected to grow at the current pace this year

	2021	2023	2024 (projected)
Depreciation And Amortization	232K	960K	596.5K
Interest Income	1.2M	2.1M	1.2M

Depreciation And Amortization Interest Income

Candel Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.35	0.61	0.29	0.09	0.6	0.76	0.66	-0.83	-0.49	0.65	0.85	0.66	0.54	0.59	0.43	0.99	0.63	-0.33	-0.67	0.9	0.51	-0.77	0.88	0.58	0.99
Short Long Term Debt Total	0.35		0.76	0.87	-0.26	-0.24	0.77	0.8	-0.2	-0.92	0.08	0.59	0.8	0.31	0.22	0.9	0.25	0.74	-0.6	-0.79	0.39	0.89	-0.76	0.68	0.86	0.27
Other Current Liab	0.61	0.76		0.79	-0.05	0.37	0.82	0.99	-0.74	-0.89	0.66	0.93	0.99	0.25	0.69	0.74	0.5	0.86	-0.41	-0.85	0.73	0.93	-0.81	0.81	0.97	0.53
Total Current Liabilities	0.29	0.87	0.79		0.19	0.03	0.79	0.76	-0.27	-0.96	0.35	0.61	0.76	0.39	0.55	0.61	0.18	0.72	-0.7	-0.81	0.5	0.82	-0.75	0.58	0.81	0.21
Total Stockholder Equity	0.09	-0.26	-0.05	0.19		0.59	0.22	-0.14	-0.15	-0.07	0.48	0.06	-0.12	0.54	0.58	-0.54	0.12	0.07	-0.19	-0.17	0.39	-0.17	-0.18	0.01	-0.13	0.12
Other Liab	0.6	-0.24	0.37	0.03	0.59		0.35	0.31	-0.83	-0.11	0.92	0.6	0.33	0.33	0.81	-0.22	0.61	0.34	0.07	-0.32	0.75	0.12	-0.35	0.41	0.22	0.61
Net Tangible Assets	0.76	0.77	0.82	0.79	0.22	0.35		0.84	-0.62	-0.91	0.54	0.85	0.85	0.73	0.62	0.68	0.68	0.92	-0.53	-0.98	0.87	0.85	-0.99	0.94	0.86	0.71
Property Plant And Equipment Net	0.66	0.8	0.99	0.76	-0.14	0.31	0.84		-0.73	-0.89	0.6	0.93	1.0	0.28	0.61	0.81	0.55	0.88	-0.39	-0.87	0.73	0.96	-0.84	0.86	0.99	0.58
Net Debt	-0.83	-0.2	-0.74	-0.27	-0.15	-0.83	-0.62	-0.73		0.44	-0.9	-0.9	-0.73	-0.3	-0.77	-0.32	-0.79	-0.66	0.05	0.61	-0.88	-0.55	0.63	-0.75	-0.64	-0.8
Retained Earnings	-0.49	-0.92	-0.89	-0.96	-0.07	-0.11	-0.91	-0.89	0.44		-0.42	-0.76	-0.89	-0.48	-0.55	-0.77	-0.38	-0.87	0.61	0.93	-0.65	-0.93	0.89	-0.78	-0.93	-0.41
Accounts Payable	0.65	0.08	0.66	0.35	0.48	0.92	0.54	0.6	-0.9	-0.42		0.8	0.61	0.27	0.95	0.03	0.61	0.52	-0.18	-0.52	0.83	0.41	-0.52	0.54	0.51	0.62
Cash	0.85	0.59	0.93	0.61	0.06	0.6	0.85	0.93	-0.9	-0.76	0.8		0.93	0.38	0.77	0.61	0.77	0.82	-0.38	-0.83	0.9	0.81	-0.84	0.9	0.88	0.79
Non Current Assets Total	0.66	0.8	0.99	0.76	-0.12	0.33	0.85	1.0	-0.73	-0.89	0.61	0.93		0.29	0.62	0.8	0.55	0.88	-0.39	-0.87	0.74	0.96	-0.84	0.86	0.99	0.58
Non Currrent Assets Other	0.54	0.31	0.25	0.39	0.54	0.33	0.73	0.28	-0.3	-0.48	0.27	0.38	0.29		0.31	0.23	0.53	0.64	-0.2	-0.71	0.68	0.37	-0.75	0.65	0.35	0.55
Other Assets	0.59	0.22	0.69	0.55	0.58	0.81	0.62	0.61	-0.77	-0.55	0.95	0.77	0.62	0.31		0.04	0.54	0.51	-0.45	-0.57	0.8	0.44	-0.57	0.52	0.54	0.55
Long Term Debt	0.43	0.9	0.74	0.61	-0.54	-0.22	0.68	0.81	-0.32	-0.77	0.03	0.61	0.8	0.23	0.04		0.33	0.76	-0.26	-0.73	0.37	0.89	-0.7	0.74	0.85	0.35
Cash And Short Term Investments	0.99	0.25	0.5	0.18	0.12	0.61	0.68	0.55	-0.79	-0.38	0.61	0.77	0.55	0.53	0.54	0.33		0.54	-0.3	-0.58	0.86	0.4	-0.7	0.82	0.47	1.0
Common Stock Total Equity	0.63	0.74	0.86	0.72	0.07	0.34	0.92	0.88	-0.66	-0.87	0.52	0.82	0.88	0.64	0.51	0.76	0.54		-0.2	-0.97	0.79	0.93	-0.94	0.91	0.92	0.56
Common Stock Shares Outstanding	-0.33	-0.6	-0.41	-0.7	-0.19	0.07	-0.53	-0.39	0.05	0.61	-0.18	-0.38	-0.39	-0.2	-0.45	-0.26	-0.3	-0.2		0.41	-0.32	-0.34	0.45	-0.32	-0.38	-0.3
Non Current Liabilities Total	-0.67	-0.79	-0.85	-0.81	-0.17	-0.32	-0.98	-0.87	0.61	0.93	-0.52	-0.83	-0.87	-0.71	-0.57	-0.73	-0.58	-0.97	0.41		-0.83	-0.91	0.99	-0.92	-0.91	-0.61
Other Current Assets	0.9	0.39	0.73	0.5	0.39	0.75	0.87	0.73	-0.88	-0.65	0.83	0.9	0.74	0.68	0.8	0.37	0.86	0.79	-0.32	-0.83		0.63	-0.87	0.89	0.69	0.87
Other Stockholder Equity	0.51	0.89	0.93	0.82	-0.17	0.12	0.85	0.96	-0.55	-0.93	0.41	0.81	0.96	0.37	0.44	0.89	0.4	0.93	-0.34	-0.91	0.63		-0.86	0.83	0.99	0.43
Total Liab	-0.77	-0.76	-0.81	-0.75	-0.18	-0.35	-0.99	-0.84	0.63	0.89	-0.52	-0.84	-0.84	-0.75	-0.57	-0.7	-0.7	-0.94	0.45	0.99	-0.87	-0.86		-0.96	-0.86	-0.72
Net Invested Capital	0.88	0.68	0.81	0.58	0.01	0.41	0.94	0.86	-0.75	-0.78	0.54	0.9	0.86	0.65	0.52	0.74	0.82	0.91	-0.32	-0.92	0.89	0.83	-0.96		0.85	0.83
Property Plant And Equipment Gross	0.58	0.86	0.97	0.81	-0.13	0.22	0.86	0.99	-0.64	-0.93	0.51	0.88	0.99	0.35	0.54	0.85	0.47	0.92	-0.38	-0.91	0.69	0.99	-0.86	0.85		0.5
Total Current Assets	0.99	0.27	0.53	0.21	0.12	0.61	0.71	0.58	-0.8	-0.41	0.62	0.79	0.58	0.55	0.55	0.35	1.0	0.56	-0.3	-0.61	0.87	0.43	-0.72	0.83	0.5

Click cells to compare fundamentals

Candel Therapeutics Account Relationship Matchups

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Candel Therapeutics is a strong investment it is important to analyze Candel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Candel Therapeutics' future performance. For an informed investment choice regarding Candel Stock, refer to the following important reports:

How To Invest In Candel

Details

Is Candel Stock a good investment?

Details

What is Candel Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.

You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.73)

Revenue Per Share

0.001

Return On Assets

(0.52)

Return On Equity

(4.81)

The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Candel Change To Liabilities vs Begin Period Cash Flow Analysis

Change To Liabilities vs Begin Period Cash Flow

Change To Liabilities vs Begin Period Cash Flow Correlation Analysis

Correlation Coefficient

Change To Liabilities

Begin Period Cash Flow

Candel Therapeutics fundamental ratios Correlations

Candel Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Other Current Liab
Non Current Assets Total	+ 0.99	Other Current Liab

Total Liab	- 0.99	Net Tangible Assets
Non Current Liabilities Total	- 0.98	Net Tangible Assets
Non Current Liabilities Total	- 0.97	Common Stock Total Equity
Net Invested Capital	- 0.96	Total Liab
Retained Earnings	- 0.96	Total Current Liabilities
Total Liab	- 0.94	Common Stock Total Equity